OncoMatch/Clinical Trials/NCT05992584
Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC
Is NCT05992584 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Lenvatinib, sintilimab plus SIRT for hepatocellular carcinoma.
Treatment: Lenvatinib, sintilimab plus SIRT — This study is conducted to evaluate the efficacy and safety of lenvatinib, sintilimab plus Y-90 selective internal radiation therapy (SIRT) for patients with unresectable intermediate-advanced hepatocellular carcinoma (HCC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC STAGE B, BCLC STAGE C (BCLC)
Unresectable HCC (BCLC stage B/C)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: hepatic arterial infusion chemotherapy
Patients who previously received hepatic arterial infusion chemotherapy (HAIC)
Cannot have received: transarterial chemoembolization
transarterial chemoembolization (TACE)
Cannot have received: transarterial embolization
transarterial embolization (TAE)
Cannot have received: radiotherapy
radiotherapy
Cannot have received: systemic therapy
systemic therapy
Cannot have received: immunotherapy
immunotherapy for HCC
Lab requirements
Blood counts
Peripheral blood white blood cell count <3×10^9/L, platelet count <50×10^9/L, prolongation of prothrombin time ≥ 4 seconds
Liver function
Child-Pugh score 5-7
Child-Pugh score 5-7; Peripheral blood white blood cell count <3×10^9/L, platelet count <50×10^9/L; Prolongation of prothrombin time ≥ 4 seconds; Severe organ dysfunction (heart, lungs, kidneys)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify